Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded down 4% on Thursday . The company traded as low as $7.24 and last traded at $7.36, with a volume of 57,285 shares. The stock had previously closed at $7.67.

A number of analysts recently weighed in on the stock. Jefferies Group lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price objective for the company. in a research note on Wednesday, June 1st. Raymond James Financial Inc. assumed coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, April 6th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Sunday, June 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. Karyopharm Therapeutics currently has an average rating of “Buy” and an average price target of $19.50.

The stock’s 50-day moving average is $7.47 and its 200-day moving average is $7.79. The company’s market cap is $264.67 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.01. Analysts forecast that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current year.

In related news, major shareholder Ltd Chione sold 7,074 shares of the firm’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $8.51, for a total transaction of $60,199.74. Following the completion of the sale, the insider now directly owns 8,568,744 shares of the company’s stock, valued at approximately $72,920,011.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent quarter.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.